Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases Oncol Ther (2018) 6:157–171 https://doi.org/10.1007/s40487-018-0088-0 ORIGINAL RESEARCH Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases . . . . . . Shunji Takahashi Seigo Kinuya Norio Nonomura Nobuo Shinohara Kazuhiro Suzuki Hiroyoshi Suzuki . . . . . Katsumasa Nakamura Takefumi Satoh Ukihide Tateishi Toshiyuki Yoneda Hiroyuki Horikoshi . . . . . . Tsukasa Igawa Takao Kamai Mitsuru Koizumi Takeo Kosaka Nobuaki Matsubara Hideaki Miyake . . . . . Atsushi Mizokami Takashi Mizowaki Naoki Nakamura Masahiro Nozawa Takeo Takahashi . . . . Hiroji Uemura Motohide Uemura Akira Yokomizo Mana Yoshimura Yoshiyuki Kakehi Received: September 11, 2018 / Published online: December 11, 2018 The Author(s) 2018 emitter radium-223 dichloride (Ra-223), Japa- ABSTRACT nese clinicians are faced with making difficult decisions on the choice of optimal treatment Introduction: The incidence of prostate cancer strategy. In such situations, guidance based on in Japan continues to increase, necessitating the expert opinions can be beneficial. continued development of effective therapies Methods: A panel meeting of 27 Japanese and strategies. Recent advances in treatments experts in the management of prostate cancer have improved the prognosis of metastatic dis- was held to share opinions and to establish ease http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases

Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/japanese-expert-panel-meeting-on-the-management-of-prostate-cancer-5D65lVyB4K
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0088-0
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:157–171 https://doi.org/10.1007/s40487-018-0088-0 ORIGINAL RESEARCH Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases . . . . . . Shunji Takahashi Seigo Kinuya Norio Nonomura Nobuo Shinohara Kazuhiro Suzuki Hiroyoshi Suzuki . . . . . Katsumasa Nakamura Takefumi Satoh Ukihide Tateishi Toshiyuki Yoneda Hiroyuki Horikoshi . . . . . . Tsukasa Igawa Takao Kamai Mitsuru Koizumi Takeo Kosaka Nobuaki Matsubara Hideaki Miyake . . . . . Atsushi Mizokami Takashi Mizowaki Naoki Nakamura Masahiro Nozawa Takeo Takahashi . . . . Hiroji Uemura Motohide Uemura Akira Yokomizo Mana Yoshimura Yoshiyuki Kakehi Received: September 11, 2018 / Published online: December 11, 2018 The Author(s) 2018 emitter radium-223 dichloride (Ra-223), Japa- ABSTRACT nese clinicians are faced with making difficult decisions on the choice of optimal treatment Introduction: The incidence of prostate cancer strategy. In such situations, guidance based on in Japan continues to increase, necessitating the expert opinions can be beneficial. continued development of effective therapies Methods: A panel meeting of 27 Japanese and strategies. Recent advances in treatments experts in the management of prostate cancer have improved the prognosis of metastatic dis- was held to share opinions and to establish ease

Journal

Oncology and Therapy – Springer Journals

Published: Dec 11, 2018

References

  • Alpha emitter radium-223 and survival in metastatic prostate cancer
    Parker, C; Nilsson, S; Heinrich, D
  • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
    Sartor, O; Coleman, R; Nilsson, S
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
    Gillessen, S; Omlin, A; Attard, G
  • The Delphi technique: making sense of consensus
    Hsu, C-C; Sandford, BA
  • Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen: Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel
    Thomas, C; Bögemann, M; König, F
  • Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis
    Ost, P; Jereczek-Fossa, BA; As, NV
  • SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer
    Azzam, G; Lanciano, R; Arrigo, S
  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, ND; Sydes, MR; Clarke, NW
  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
    Vale, CL; Burdett, S; Rydzewska, LH
  • Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy
    Yang, HL; Liu, T; Wang, XM; Xu, Y; Deng, SM
  • Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
    Scher, HI; Morris, MJ; Stadler, WM
  • Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
    Uemura, K; Miyoshi, Y; Kawahara, T
  • Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
    Fitzpatrick, JM; Bellmunt, J; Fizazi, K
  • Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
    Saad, F; Shore, N; Poppel, H
  • Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    Sweeney, CJ; Chen, YH; Carducci, M
  • Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
    Fizazi, K; Tran, N; Fein, L
  • Abiraterone for prostate cancer not previously treated with hormone therapy
    James, ND; Bono, JS; Spears, MR
  • Current approaches to incorporation of radium-223 in clinical practice
    Parker, C; Heidenreich, A; Nilsson, S; Shore, N
  • Metastatic prostate cancer
    Sartor, O; Bono, JS